EyePoint, Inc. (EYPT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$4.25+0.47%
Close 2026-09-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put EYPT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve full enrollment by Q3 2026: Enrollment target missed (LUGANO primary endpoint miss) vs Q3 2026 deadline.
View ThesisRevenue is contracting — down about 93% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 78% in its worst 12-month stretch.
View RiskEYPT's growth hinges on advancing its Phase 3 wet AMD program. Recent financial performance has been steady, but the latest earnings miss indicates challenges ahead. EYPT trades at 0.2× price-to-sales, significantly below the peer median of 12×. The market appears to be pricing in more growth than the company can deliver, suggesting expectations look full. A specific risk is the missed enrollment target for the Phase 3 DME trials, which puts pressure on the thesis. Peer multiples imply a price about 47% above where it trades. This read is provisional.
Trailing returns as of 2026-09-14. EYPT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering EYPT (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for EYPT in the last 4 months.
Continue this research
Compare EYPT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EYPT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put EYPT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Advance Phase 3 wet AMD program
Mixed trial data raises concerns about Phase 3 wet AMD program.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $4.25
The last 12 months of price, then the range of analyst 12-month targets from today’s $4.25.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Advance Phase 3 wet AMD program
Wet AMD setback impacts Phase 3 program progress.
Threatens: Advance Phase 3 wet AMD program
Primary endpoint miss impacts Phase 3 wet AMD program.
Threatens: Achieve full enrollment by Q3 2026 in Phase 3 DME trials
Trial miss impacts enrollment timeline for Phase 3 DME trials.
Advances: Advance Phase 3 wet AMD program
Positive data supports advancement of Phase 3 wet AMD program.
Advances: Advance Phase 3 wet AMD program
Durability of DURAVYU supports Phase 3 wet AMD program.